The study identifies optimized peptide-derived irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity in cell culture.
Answers are grounded in this paper and cite their sources.
Cell-culture potency supports further preclinical optimization of 3CP inhibitors; leaves open in vivo and clinical translation.
The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (kobs/[I]) ranging from 60 to 280 000 M-1 s-1 and antiviral EC50's which approach 0.15 microM. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (kobs/[I] = 800 000 M-1 s-1) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 microM). A 1.9 A crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-2 3CP is also detailed.
No takes yet. Share an insight, caveat, or question.
Dragovich et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: